Tom van Blarcom
Technik-/Wissenschafts-/F&E-Leiter bei KYVERNA THERAPEUTICS, INC.
Profil
Tom van Blarcom is currently the Senior Vice President & Head-Research at Kyverna Therapeutics, Inc. He previously worked as the Senior Director-Medical at Genentech, Inc., the Executive Director & Head-Protein Engineering at Allogene Therapeutics, Inc., and the Vice President at Horizon Therapeutics, Inc. Dr. van Blarcom completed his undergraduate studies at Universite Paris Est.
Creteil Val De Marne and North Carolina State University.
He holds a doctorate degree from The University of Texas at Austin.
Aktive Positionen von Tom van Blarcom
| Unternehmen | Position | Beginn |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Tom van Blarcom
| Unternehmen | Position | Ende |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
| ALLOGENE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Corporate Officer/Principal | - |
Ausbildung von Tom van Blarcom
| Universite Paris Est Creteil Val De Marne | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |